Physiomics PLC Contract Award
08 August 2023 - 4:45PM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
08 August 2023
8 August 2023
Physiomics plc
("Physiomics") or ("the Company")
Contract award
Physiomics plc (AIM: PYC), a leading mathematical modelling
company, supporting development of oncology drugs and personalised
medicine solutions, is pleased to announce that it has been awarded
a further contract by existing client, Numab Therapeutics
("Numab"). The project involves PKPD modelling in support of one of
Numab's clinical programs and follows on from earlier work
conducted by Physiomics on the same asset. The project will span
two years of the clinical program.
Physiomics CEO, Dr Jim Millen, commented: "We are delighted that
we have a further opportunity to support Numab with its exciting
clinical pipeline and look forward to working once again with their
talented team."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling
techniques with cancer biology expertise, to help biotech and
pharma companies streamline their drug development journeys. Our
approach is to derive insight from all relevant data in order to
de-risk decision making and optimise design of pre-clinical and
clinical studies. Through use of bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the
development of over 100 projects, over 50 targets, and 75 drugs.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab
Therapeutics & CRUK.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUPURWRUPWUQR
(END) Dow Jones Newswires
August 08, 2023 02:45 ET (06:45 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024